Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03604315 · ClinicalTrials.gov registry record · Phase 1

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

A Phase 1 study of Breast Carcinoma and Recurrent Ovarian Carcinoma, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
300
Enrollment target
1
Study location

NCT03604315 is a Phase 1 study of Breast Carcinoma and Recurrent Ovarian Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 300 participants, below the 768-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03604315, a Phase 1 study of Breast Carcinoma and Recurrent Ovarian Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET/CT uses a scanner to make detailed, computerized pictures of areas inside the body. PET/CT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.

Conditions Studied

Breast Carcinoma Recurrent Ovarian Carcinoma Ovarian Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Primary Peritoneal Carcinoma Primary Peritoneal Carcinoma Fallopian Tube Carcinoma Solid Neoplasm

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Positron Emission Tomography
  • RADIATION Fludeoxyglucose F-18
  • RADIATION Fluorine F 18 Fluorthanatrace

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2018-12-18
Est. Completion 2027-06-30
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03604315

The ClinicalTrials.gov registry entry for NCT03604315 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 768-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (61% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.

NCT03604315 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03604315 about?

NCT03604315 is a clinical study titled "Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF". This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into t...

What is the current status of trial NCT03604315?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2018-12-18. Estimated completion is 2027-06-30.

What conditions does trial NCT03604315 study?

This clinical trial studies the following conditions: Breast Carcinoma, Recurrent Ovarian Carcinoma, Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma.

What interventions are being tested in trial NCT03604315?

The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Fludeoxyglucose F-18 (RADIATION), Fluorine F 18 Fluorthanatrace (RADIATION).

Who is sponsoring clinical trial NCT03604315?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03604315 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Carcinoma

All registered trials for this condition

Recurrent Ovarian Carcinoma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.